Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries

DS. Courvoisier, K. Chatzidionysiou, D. Mongin, K. Lauper, X. Mariette, J. Morel, JE. Gottenberg, SA. Bergstra, MP. Suarez, C. Codreanu, TK. Kvien, MJ. Santos, K. Pavelka, ML. Hetland, J. Askling, C. Turesson, S. Kubo, Y. Tanaka, F. Iannone, D....

. 2021 ; 60 (2) : 820-828. [pub] 20210201

Language English Country Great Britain

Document type Journal Article, Observational Study

Persistent link   https://www.medvik.cz/link/bmc21019385

OBJECTIVES: RF and ACPA are used as diagnostic tools and their presence has been associated with clinical response to some biologic DMARDs (bDMARDs) in RA. This study compared the impact of seropositivity on drug discontinuation and effectiveness of bDMARDs in patients with RA, using head-to-head comparisons in a real-world setting. METHODS: We conducted a pooled analysis of 16 observational RA registries. Inclusion criteria were a diagnosis of RA, initiation of treatment with rituximab (RTX), abatacept (ABA), tocilizumab (TCZ) or TNF inhibitors (TNFis) and available information on RF and/or ACPA status. Drug discontinuation was analysed using Cox regression, including drug, seropositivity, their interaction, adjusting for concomitant and past treatments and patient and disease characteristics and accounting for country and calendar year of bDMARD initiation. Effectiveness was analysed using the Clinical Disease Activity Index evolution over time. RESULTS: Among the 27 583 eligible patients, the association of seropositivity with drug discontinuation differed across bDMARDs (P for interaction <0.001). The adjusted hazard ratios for seropositive compared with seronegative patients were 1.01 (95% CI 0.95, 1.07) for TNFis, 0.89 (0.78, 1.02)] for TCZ, 0.80 (0.72, 0.88) for ABA and 0.70 (0.59, 0.84) for RTX. Adjusted differences in remission and low disease activity rates between seropositive and seronegative patients followed the same pattern, with no difference in TNFis, a small difference in TCZ, a larger difference in ABA and the largest difference in RTX (Lundex remission difference +5.9%, low disease activity difference +11.6%). CONCLUSION: Seropositivity was associated with increased effectiveness of non-TNFi bDMARDs, especially RTX and ABA, but not TNFis.

1st Department of Internal Medicine University of Occupational and Environmental Health Kitakyushu Japan

Center of Rheumatic Diseases University of Medicine and Pharmacy Bucharest Romania

Centre for Epidemiology Versus Arthritis Centre for Musculoskeletal Research University of Manchester Manchester UK

Clinical Epidemiology Karolinska Institutet Stockholm Sweden

Clinical Medicine University of Copenhagen Copenhagen Denmark

DANBIO Registry and Copenhagen Center for Arthritis Research Rigshospitalet Glostrup Denmark

Institut de Recherche en Rhumatologie de Montréal Centre hospitalier de l'Université de Montréal and Université de Montréal Montréal Canada

Italian Group for the Study of Early Arthritis University Hospital of Bari Bari Italy

Rheumatology 5 A Nasonova Research Institute of Rheumatology Moscow Russia

Rheumatology and Clinical Immunology Amsterdam University Medical Centers Amsterdam The Netherlands

Rheumatology Charles University Prague Czech Republic

Rheumatology CHU and University of Montpellier Montpellier France

Rheumatology Clinical University Hospital Santiago de Compostela Spain

Rheumatology Diakonhjemmet Hospital Oslo Norway

Rheumatology Hospital Garcia de Orta Almada Portugal

Rheumatology Karolinska Institutet Stockholm Sweden

Rheumatology Leiden University Medical Center Leiden The Netherlands

Rheumatology Skåne University Hospital Malmö Sweden

Rheumatology Université Paris Sud AP HP Paris France

Rheumatology University Hospital of Strasbourg Strasbourg France

Rheumatology University Hospitals of Geneva Geneva Switzerland

Rheumatology University Medical Centre Ljubljana Ljubljana Slovenia

ROB FIN Registry Helsinki University Hospital and Helsinki University Helsinki Finland

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019385
003      
CZ-PrNML
005      
20210830100939.0
007      
ta
008      
210728s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/rheumatology/keaa393 $2 doi
035    __
$a (PubMed)32810263
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Courvoisier, Delphine S $u Rheumatology, University Hospitals of Geneva, Geneva, Switzerland
245    14
$a The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries / $c DS. Courvoisier, K. Chatzidionysiou, D. Mongin, K. Lauper, X. Mariette, J. Morel, JE. Gottenberg, SA. Bergstra, MP. Suarez, C. Codreanu, TK. Kvien, MJ. Santos, K. Pavelka, ML. Hetland, J. Askling, C. Turesson, S. Kubo, Y. Tanaka, F. Iannone, D. Choquette, DC. Nordström, Z. Rotar, G. Lukina, C. Gabay, R. Van Vollenhoven, A. Finckh
520    9_
$a OBJECTIVES: RF and ACPA are used as diagnostic tools and their presence has been associated with clinical response to some biologic DMARDs (bDMARDs) in RA. This study compared the impact of seropositivity on drug discontinuation and effectiveness of bDMARDs in patients with RA, using head-to-head comparisons in a real-world setting. METHODS: We conducted a pooled analysis of 16 observational RA registries. Inclusion criteria were a diagnosis of RA, initiation of treatment with rituximab (RTX), abatacept (ABA), tocilizumab (TCZ) or TNF inhibitors (TNFis) and available information on RF and/or ACPA status. Drug discontinuation was analysed using Cox regression, including drug, seropositivity, their interaction, adjusting for concomitant and past treatments and patient and disease characteristics and accounting for country and calendar year of bDMARD initiation. Effectiveness was analysed using the Clinical Disease Activity Index evolution over time. RESULTS: Among the 27 583 eligible patients, the association of seropositivity with drug discontinuation differed across bDMARDs (P for interaction <0.001). The adjusted hazard ratios for seropositive compared with seronegative patients were 1.01 (95% CI 0.95, 1.07) for TNFis, 0.89 (0.78, 1.02)] for TCZ, 0.80 (0.72, 0.88) for ABA and 0.70 (0.59, 0.84) for RTX. Adjusted differences in remission and low disease activity rates between seropositive and seronegative patients followed the same pattern, with no difference in TNFis, a small difference in TCZ, a larger difference in ABA and the largest difference in RTX (Lundex remission difference +5.9%, low disease activity difference +11.6%). CONCLUSION: Seropositivity was associated with increased effectiveness of non-TNFi bDMARDs, especially RTX and ABA, but not TNFis.
650    12
$a antirevmatika $x klasifikace $x imunologie $x terapeutické užití $7 D018501
650    12
$a revmatoidní artritida $x diagnóza $x farmakoterapie $x epidemiologie $x imunologie $7 D001172
650    12
$a biologické přípravky $x klasifikace $x imunologie $x terapeutické užití $7 D001688
650    _2
$a lékové interakce $x imunologie $7 D004347
650    _2
$a trvání terapie $7 D000081206
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mezinárodní spolupráce $7 D007391
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a monitorování imunologické $x metody $x statistika a číselné údaje $7 D015166
650    _2
$a posouzení stavu pacienta $7 D062072
650    _2
$a výběr pacientů $7 D018579
650    _2
$a registrace $x statistika a číselné údaje $7 D012042
650    _2
$a revmatoidní faktor $x krev $7 D012217
650    _2
$a výsledek terapie $7 D016896
650    _2
$a nenasazení léčby $x statistika a číselné údaje $7 D028761
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Chatzidionysiou, Katarina $u Rheumatology, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Mongin, Denis $u Rheumatology, University Hospitals of Geneva, Geneva, Switzerland
700    1_
$a Lauper, Kim $u Rheumatology, University Hospitals of Geneva, Geneva, Switzerland $u Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK
700    1_
$a Mariette, Xavier $u Rheumatology, Université Paris Sud, AP-HP, Paris, France
700    1_
$a Morel, Jacques $u Rheumatology, CHU and University of Montpellier, Montpellier, France
700    1_
$a Gottenberg, Jacques-Eric $u Rheumatology, University Hospital of Strasbourg, Strasbourg, France
700    1_
$a Bergstra, Sytske Anne $u Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
700    1_
$a Suarez, Manuel Pombo $u Rheumatology, Clinical University Hospital, Santiago de Compostela, Spain
700    1_
$a Codreanu, Catalin $u Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania
700    1_
$a Kvien, Tore K $u Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
700    1_
$a Santos, Maria Jose $u Rheumatology, Hospital Garcia de Orta, Almada, Portugal
700    1_
$a Pavelka, Karel $u Rheumatology, Charles University, Prague, Czech Republic
700    1_
$a Hetland, Merete L $u DANBIO Registry and Copenhagen Center for Arthritis Research, Rigshospitalet, Glostrup, Denmark $u Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Askling, Johan $u Clinical Epidemiology, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Turesson, Carl $u Rheumatology, Skåne University Hospital, Malmö, Sweden
700    1_
$a Kubo, Satoshi $u First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
700    1_
$a Tanaka, Yoshiya $u First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
700    1_
$a Iannone, Florenzo $u Italian Group for the Study of Early Arthritis, University Hospital of Bari, Bari, Italy
700    1_
$a Choquette, Denis $u Institut de Recherche en Rhumatologie de Montréal, Centre hospitalier de l'Université de Montréal and Université de Montréal, Montréal, Canada
700    1_
$a Nordström, Dan C $u ROB-FIN Registry, Helsinki University Hospital and Helsinki University, Helsinki, Finland
700    1_
$a Rotar, Ziga $u Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
700    1_
$a Lukina, Galina $u Rheumatology, V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia
700    1_
$a Gabay, Cem $u Rheumatology, University Hospitals of Geneva, Geneva, Switzerland
700    1_
$a Van Vollenhoven, Ronald $u Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands
700    1_
$a Finckh, Axel $u Rheumatology, University Hospitals of Geneva, Geneva, Switzerland
773    0_
$w MED00011379 $t Rheumatology (Oxford, England) $x 1462-0332 $g Roč. 60, č. 2 (2021), s. 820-828
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32810263 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100939 $b ABA008
999    __
$a ok $b bmc $g 1690249 $s 1139831
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 60 $c 2 $d 820-828 $e 20210201 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options